vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $334.0M, roughly 1.0× WYNDHAM HOTELS & RESORTS, INC.). HAEMONETICS CORP runs the higher net margin — 13.2% vs -18.0%, a 31.2% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $87.2M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -4.6%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
HAE vs WH — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $334.0M |
| Net Profit | $44.7M | $-60.0M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | — |
| Net Margin | 13.2% | -18.0% |
| Revenue YoY | -2.7% | -76.3% |
| Net Profit YoY | 19.3% | -170.6% |
| EPS (diluted) | $0.95 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $339.0M | $334.0M | ||
| Q3 25 | $327.3M | $382.0M | ||
| Q2 25 | $321.4M | $397.0M | ||
| Q1 25 | $330.6M | $316.0M | ||
| Q4 24 | $348.5M | $336.0M | ||
| Q3 24 | $345.5M | $396.0M | ||
| Q2 24 | $336.2M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $44.7M | $-60.0M | ||
| Q3 25 | $38.7M | $105.0M | ||
| Q2 25 | $34.0M | $87.0M | ||
| Q1 25 | $58.0M | $61.0M | ||
| Q4 24 | $37.5M | $85.0M | ||
| Q3 24 | $33.8M | $102.0M | ||
| Q2 24 | $38.4M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | -11.4% | ||
| Q3 25 | 17.9% | 46.6% | ||
| Q2 25 | 16.8% | 37.8% | ||
| Q1 25 | 21.6% | 35.4% | ||
| Q4 24 | 16.9% | 38.4% | ||
| Q3 24 | 15.0% | 43.2% | ||
| Q2 24 | 11.8% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | 13.2% | -18.0% | ||
| Q3 25 | 11.8% | 27.5% | ||
| Q2 25 | 10.6% | 21.9% | ||
| Q1 25 | 17.5% | 19.3% | ||
| Q4 24 | 10.8% | 25.3% | ||
| Q3 24 | 9.8% | 25.8% | ||
| Q2 24 | 11.4% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $0.95 | $-0.77 | ||
| Q3 25 | $0.81 | $1.36 | ||
| Q2 25 | $0.70 | $1.13 | ||
| Q1 25 | $1.17 | $0.78 | ||
| Q4 24 | $0.74 | $1.06 | ||
| Q3 24 | $0.66 | $1.29 | ||
| Q2 24 | $0.74 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $64.0M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $468.0M |
| Total Assets | $2.5B | $4.2B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $363.4M | $64.0M | ||
| Q3 25 | $296.4M | $70.0M | ||
| Q2 25 | $292.9M | $50.0M | ||
| Q1 25 | $306.8M | $48.0M | ||
| Q4 24 | $320.8M | $103.0M | ||
| Q3 24 | $299.3M | $72.0M | ||
| Q2 24 | $344.4M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $2.5B | ||
| Q3 25 | $1.2B | $2.6B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.2B | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $911.5M | $468.0M | ||
| Q3 25 | $849.2M | $583.0M | ||
| Q2 25 | $882.3M | $570.0M | ||
| Q1 25 | $820.8M | $579.0M | ||
| Q4 24 | $906.9M | $650.0M | ||
| Q3 24 | $878.9M | $583.0M | ||
| Q2 24 | $905.4M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $2.5B | $4.2B | ||
| Q3 25 | $2.4B | $4.3B | ||
| Q2 25 | $2.5B | $4.3B | ||
| Q1 25 | $2.5B | $4.2B | ||
| Q4 24 | $2.5B | $4.2B | ||
| Q3 24 | $2.5B | $4.2B | ||
| Q2 24 | $2.5B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | 5.37× | ||
| Q3 25 | 1.44× | 4.43× | ||
| Q2 25 | 1.39× | 4.44× | ||
| Q1 25 | 1.49× | 4.29× | ||
| Q4 24 | — | 3.72× | ||
| Q3 24 | — | 4.19× | ||
| Q2 24 | — | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $367.0M |
| Free Cash FlowOCF − Capex | $87.2M | $168.0M |
| FCF MarginFCF / Revenue | 25.7% | 50.3% |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $93.6M | $152.0M | ||
| Q3 25 | $111.3M | $86.0M | ||
| Q2 25 | $17.4M | $70.0M | ||
| Q1 25 | $116.6M | $59.0M | ||
| Q4 24 | $43.8M | $134.0M | ||
| Q3 24 | $48.8M | $79.0M | ||
| Q2 24 | $-27.4M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $87.2M | $136.0M | ||
| Q3 25 | $106.3M | $75.0M | ||
| Q2 25 | $13.6M | $58.0M | ||
| Q1 25 | $100.9M | $52.0M | ||
| Q4 24 | $35.2M | $109.0M | ||
| Q3 24 | $39.4M | $71.0M | ||
| Q2 24 | $-33.1M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | 25.7% | 40.7% | ||
| Q3 25 | 32.5% | 19.6% | ||
| Q2 25 | 4.2% | 14.6% | ||
| Q1 25 | 30.5% | 16.5% | ||
| Q4 24 | 10.1% | 32.4% | ||
| Q3 24 | 11.4% | 17.9% | ||
| Q2 24 | -9.8% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 4.8% | ||
| Q3 25 | 1.5% | 2.9% | ||
| Q2 25 | 1.2% | 3.0% | ||
| Q1 25 | 4.7% | 2.2% | ||
| Q4 24 | 2.5% | 7.4% | ||
| Q3 24 | 2.7% | 2.0% | ||
| Q2 24 | 1.7% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | 0.82× | ||
| Q2 25 | 0.51× | 0.80× | ||
| Q1 25 | 2.01× | 0.97× | ||
| Q4 24 | 1.17× | 1.58× | ||
| Q3 24 | 1.44× | 0.77× | ||
| Q2 24 | -0.71× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
